ADAR1 Capital Management »

4d Molecular Therapeutics In shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of 4d Molecular Therapeutics In (FDMT) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in 4d Molecular Therapeutics In

Tip: Access up to 7 years of quarterly data

All positions including 4d Molecular Therapeutics In held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in 4d Molecular Therapeutics In by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $64k 2.0k 31.86

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding 4d Molecular Therapeutics In

RA Capital Management
BlackRock
VR Adviser
Goldman Sachs Group
Deep Track Capital
BVF
Henderson Group
Viking Global Investors
Vanguard Group
State Street Corporation
Morgan Stanley
Novo A/S
Redmile Group
Geode Capital Management
Eventide Asset Management

View all funds holding 4d Molecular Therapeutics In